Unfortunately, most GBM are IDH-1 wild type and unmethylated MGMT becomig aggressive and resistant to therapies included the new immune checkpoint inhibitors due to the “cold tumor” phenotype [7–9]. This evidence concerns the gene IDH1 and neoplasm.